酮咯酸使用与食管癌术后吻合口漏的关系
本研究回顾性分析2006至2018年单中心1019例食管腺癌切除术患者,评估围术期酮咯酸使用与吻合口漏的关联。结论认为酮咯酸作为加速康复方案组成部分不增加吻合口漏风险。
要点
- 食管切除术患者围术期使用酮咯酸与吻合口漏无显著关联。
- 酮咯酸使用率从2006年49%升至2016年92%,同期吻合口漏发生率从15%降至2%。
核心结论
- 食管切除术后使用酮咯酸不增加吻合口漏风险,可作为加速康复路径的镇痛选择。
研究设计与样本
- 单中心回顾性队列研究,纳入2006至2018年因腺癌行食管切除术的患者1019例。
主要发现
- 686例(67%)接受了酮咯酸,使用率从2006年49%上升至2016年92%。
- 87例(9%)发生吻合口漏,发生率从2006年15%(11/72)降至2018年2%(2/83)。
临床怎么用
- 在食管切除术后的加速康复路径中,可考虑使用酮咯酸作为非阿片类镇痛药物而不必担心增加吻合口漏风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Recent evidence has shown an association between postoperative ketorolac use and anastomotic leak in patients undergoing intestinal and colorectal operations, but this relationship has been minimally explored after esophagectomy. As the use of nonopioid pain control and enhanced recovery protocols is increasingly prioritized, determination of a possible correlation between perioperative ketorolac use and leak is essential. METHODS: Records of patients undergoing esophagectomy for adenocarcinoma at a single institution from 2006 to 2018 reviewed for occurrence of anastomotic leak. Institutional pharmacy records were queried for ketorolac administration during the surgical case through the time of discharge. Multivariable logistic regression was used to determine the relationship between ketorolac administration and anastomotic leak. RESULTS: A total of 1019 patients met inclusion criteria, the majority of whom were male (907, 89%) with a median age of 62 years. Patients predominantly presented with locoregionally advanced disease and were treated with initial chemoradiation. Ketorolac was administered to 686 patients (67%); use was observed to increase over the study period from 49% in 2006 to 92% in 2016. Conversely, anastomotic leak occurred in 87 patients (9%) overall and decreased over time from 15% (11/72) in 2006 to 2% (2/83) in 2018. Upon multivariable analysis, neither ketorolac administration evaluated as a categoric variable (odds ratio, 0.99; P = .958) or as a continuous variable using dose (odds ratio, 1.00; P = .843) demonstrated an association with anastomotic leak. CONCLUSIONS: Ketorolac in the postoperative period after esophagectomy has become an integral component of enhanced recovery pathways and does not appear to be associated with anastomotic leak.
引用
- Corsini EM, Hofstetter WL. Ketorolac use and anastomotic leak in patients with esophageal cancer. J Thorac Cardiovasc Surg. 2020. PMID: 32340809. doi:10.1016/j.jtcvs.2020.02.133
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。